FogPharma Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 104

Employees
  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $107M

  • Investors
  • 18

FogPharma General Information

Description

Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. The company's mini proteins (CPMPs) are a broad new class of medicines that can drug target beyond the reach of conventional therapeutics, enabling physicians to treat cancer-related diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 30 Acorn Park Drive
  • 6th Floor
  • Cambridge, MA 02140
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

FogPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 12-Jan-2021 $107M 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 16-May-2018 0000 0000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 18-Aug-2017 $11M $11M 0000 Completed Generating Revenue
To view FogPharma’s complete valuation and funding history, request access »

FogPharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 0,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Series A 1,434,062 $0.000100 $0.62 $7.75 $7.75 1x $7.75 8.09%
To view FogPharma’s complete cap table history, request access »

FogPharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and n
Drug Discovery
Cambridge, MA
104 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000 000000000
Jerusalem, Israel
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

000000

ute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exc
0000000000000
New Haven, CT
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

FogPharma Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunovative Therapies Formerly VC-backed Jerusalem, Israel 00 000.00 00000000000 000.00
0000000 Formerly VC-backed New Haven, CT 000 00000 000000000 00000
00000 000000000000 Formerly VC-backed Waltham, MA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 63 competitors. Get the full list »

FogPharma Patents

FogPharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020403154-A1 Technologies useful for assessing permeability Pending 11-Dec-2019 00000000
CA-3159729-A1 Technologies useful for assessing permeability Pending 11-Dec-2019 00000000
US-20210179665-A1 Collections of peptides, peptide agents, and methods of use thereof Pending 20-Aug-2018 00000000
EP-3840766-A4 Collections of peptides, peptide agents, and methods of use thereof Pending 20-Aug-2018 00000000 0
AU-2019326423-A1 Collections of peptides, peptide agents, and methods of use thereof Pending 20-Aug-2018 C07K7/06
To view FogPharma’s complete patent history, request access »

FogPharma Executive Team (13)

Name Title Board Seat Contact Info
Lihua Yu Ph.D Chief Data Officer
Keith Orford MD Chief Medical Officer & Executive Vice President, Clinical and Translational Science
David Lane Ph.D Co-Founder
Thomas Kotarakos Senior Vice President, Finance
Michael Hale Ph.D Vice President, Chemistry
You’re viewing 5 of 13 executive team members. Get the full list »

FogPharma Board Members (7)

Name Representing Role Since
Barbara Weber MD Self Board Member 000 0000
Corey Goodman Ph.D Self Chairman 000 0000
Edward Fitzgerald FogPharma Board Member 000 0000
Gregory Verdine Ph.D Self Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Jeffrey Leerink SVB Securities Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

FogPharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

FogPharma Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Casdin Capital Hedge Fund Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 18 investors. Get the full list »